<?xml version="1.0" encoding="utf-8"?> <rss version="2.0"> <channel xmlns:dc="http://dublincore.org/documents/dcmi-namespace/" xmlns:media="http://search.yahoo.com/mrss/"> <title>Sirona Biochem Corp.</title> <link>https://www.globenewswire.com/rssfeed/organization/wy9Hqy0LVpwaBD_h-kQZTQ==</link> <description>Contains the last 20 releases</description> <copyright>Copyright 2024, Sirona Biochem Corp.</copyright> <managingEditor>newsdesk@globenewswire.com (NewsDesk)</managingEditor> <lastBuildDate>Wed, 20 Nov 2024 21:30:00 GMT</lastBuildDate> <webMaster>webmaster@globenewswire.com (Webmaster)</webMaster> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2024/11/20/2984794/0/en/Sirona-Biochem-Announces-Publication-of-Groundbreaking-Study-on-TFC-1326-Compound-in-the-Journal-of-Cosmetic-Dermatology.html</guid> <link>https://www.globenewswire.com/news-release/2024/11/20/2984794/0/en/Sirona-Biochem-Announces-Publication-of-Groundbreaking-Study-on-TFC-1326-Compound-in-the-Journal-of-Cosmetic-Dermatology.html</link> <category domain="https://www.globenewswire.com/rss/stock">TSX-V:SBM</category> <category domain="https://www.globenewswire.com/rss/stock">Other OTC:SRBCF</category> <category domain="https://www.globenewswire.com/rss/stock">Frankfurt:ZSB</category> <category domain="https://www.globenewswire.com/rss/stock">XETRA:ZSB</category> <category domain="https://www.globenewswire.com/rss/ISIN">CA82967M1005</category> <title>Sirona Biochem Announces Publication of Groundbreaking Study on TFC-1326 Compound in the Journal of Cosmetic Dermatology</title> <description><![CDATA[<p>VANCOUVER, British Columbia, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) is proud to announce the publication of a pivotal research article in the prestigious <em>Journal of Cosmetic Dermatology</em>.</p>]]></description> <pubDate>Wed, 20 Nov 2024 21:30 GMT</pubDate> <dc:identifier>2984794</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Sirona Biochem Corp.</dc:contributor> <dc:modified>Wed, 20 Nov 2024 21:30 GMT</dc:modified> <dc:subject>Market Research Reports</dc:subject> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2024/09/25/2952986/0/en/SIRONA-BIOCHEM-Poised-for-Profitability-in-2025-with-Anti-Aging-Product-Rollout.html</guid> <link>https://www.globenewswire.com/news-release/2024/09/25/2952986/0/en/SIRONA-BIOCHEM-Poised-for-Profitability-in-2025-with-Anti-Aging-Product-Rollout.html</link> <category domain="https://www.globenewswire.com/rss/stock">TSX-V:SBM</category> <category domain="https://www.globenewswire.com/rss/stock">Other OTC:SRBCF</category> <category domain="https://www.globenewswire.com/rss/stock">Frankfurt:ZSB</category> <category domain="https://www.globenewswire.com/rss/stock">XETRA:ZSB</category> <category domain="https://www.globenewswire.com/rss/ISIN">CA82967M1005</category> <title>SIRONA BIOCHEM Poised for Profitability in 2025 with Anti-Aging Product Rollout</title> <description><![CDATA[<p align="justify">VANCOUVER, British Columbia, Sept. 25, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=6t9Xaj0S5jNxdDC8STOsMyWxU0d0lo5vXCQMu-NLkIZhBLZ3gA7IWXbCCE8sbQrTOxPDtDtXVja9WBrylakD_XbbaYSGrV4U80MlPZ8oGSs=" rel="nofollow" target="_blank" title="Sirona Biochem Corp">Sirona Biochem Corp</a>. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“<strong>Sirona</strong>” or the “<strong>Company</strong>”) provides the following update:</p>]]></description> <pubDate>Wed, 25 Sep 2024 13:00 GMT</pubDate> <dc:identifier>2952986</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Sirona Biochem Corp.</dc:contributor> <dc:modified>Wed, 25 Sep 2024 13:00 GMT</dc:modified> <dc:subject>Product / Services Announcement</dc:subject> <dc:subject>Major shareholder announcements</dc:subject> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2024/06/18/2900586/0/en/GlycoProteMim-Featured-in-Stonegate-Healthcare-s-Latest-Anti-Aging-Research-Report.html</guid> <link>https://www.globenewswire.com/news-release/2024/06/18/2900586/0/en/GlycoProteMim-Featured-in-Stonegate-Healthcare-s-Latest-Anti-Aging-Research-Report.html</link> <category domain="https://www.globenewswire.com/rss/stock">TSX-V:SBM</category> <category domain="https://www.globenewswire.com/rss/stock">Other OTC:SRBCF</category> <category domain="https://www.globenewswire.com/rss/stock">Frankfurt:ZSB</category> <category domain="https://www.globenewswire.com/rss/stock">XETRA:ZSB</category> <category domain="https://www.globenewswire.com/rss/ISIN">CA82967M1005</category> <title>GlycoProteMim Featured in Stonegate Healthcare’s Latest Anti-Aging Research Report</title> <description><![CDATA[<p align="justify">VANCOUVER, British Columbia, June 18, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) is pleased to announce that its innovative anti-aging ingredient, GlycoProteMim™, has been featured in Stonegate Healthcare's newly published research report, "Novel Treatments for Age-Related Skin Problems." The report provides an in-depth analysis of the latest advancements in the $12.5 billion anti-aging skincare market.<br></p>]]></description> <pubDate>Tue, 18 Jun 2024 14:35 GMT</pubDate> <dc:identifier>2900586</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Sirona Biochem Corp.</dc:contributor> <dc:modified>Tue, 18 Jun 2024 14:36 GMT</dc:modified> <dc:subject>Health</dc:subject> <dc:subject>Product / Services Announcement</dc:subject> <dc:subject>Research Analysis and Reports</dc:subject> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2024/05/07/2876691/0/en/Sirona-Biochem-Engages-Stonegate-Healthcare-Partners.html</guid> <link>https://www.globenewswire.com/news-release/2024/05/07/2876691/0/en/Sirona-Biochem-Engages-Stonegate-Healthcare-Partners.html</link> <category domain="https://www.globenewswire.com/rss/stock">TSX-V:SBM</category> <category domain="https://www.globenewswire.com/rss/stock">Other OTC:SRBCF</category> <category domain="https://www.globenewswire.com/rss/stock">Frankfurt:ZSB</category> <category domain="https://www.globenewswire.com/rss/stock">XETRA:ZSB</category> <category domain="https://www.globenewswire.com/rss/ISIN">CA82967M1005</category> <title>Sirona Biochem Engages Stonegate Healthcare Partners</title> <description><![CDATA[<p align="justify">VANCOUVER, British Columbia, May 07, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) has announced a partnership with Stonegate Healthcare Partners. Stonegate is a leading corporate advisory firm based in Dallas, Texas that offers research driven business development and investor outreach services. Leveraging Stonegate’s extensive global network of corporate and institutional investor relationships, Stonegate has begun an evaluation of Sirona’s anti-aging ingredient, GlycoProteMimTM, to effectively assess and demonstrate its market potential within the global anti-aging skincare industry.<br></p>]]></description> <pubDate>Tue, 07 May 2024 12:00 GMT</pubDate> <dc:identifier>2876691</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Sirona Biochem Corp.</dc:contributor> <dc:modified>Tue, 07 May 2024 12:01 GMT</dc:modified> <dc:subject>Partnerships</dc:subject> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2024/04/08/2858883/0/en/SIRONA-BIOCHEM-Corporate-Update-April-2024.html</guid> <link>https://www.globenewswire.com/news-release/2024/04/08/2858883/0/en/SIRONA-BIOCHEM-Corporate-Update-April-2024.html</link> <category domain="https://www.globenewswire.com/rss/stock">TSX-V:SBM</category> <category domain="https://www.globenewswire.com/rss/stock">Other OTC:SRBCF</category> <category domain="https://www.globenewswire.com/rss/stock">Frankfurt:ZSB</category> <category domain="https://www.globenewswire.com/rss/stock">XETRA:ZSB</category> <category domain="https://www.globenewswire.com/rss/ISIN">CA82967M1005</category> <title>SIRONA BIOCHEM Corporate Update April 2024</title> <description><![CDATA[<p align="justify">VANCOUVER, British Columbia, April 08, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=91VGkH6lQznNiD9bf8xUeXMeWEu4FO7kb0aANMy6TYeKUh33zSHMs8pvkfR_F6HwG1VI5TICmeB4XSSs3VpDJYSkznc2_Ac72xIbn3NbL9M=" rel="nofollow" target="_blank" title="Sirona Biochem Corp">Sirona Biochem Corp</a>. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“<strong>Sirona</strong>” or the “<strong>Company</strong>”) provides the following update:<br></p>]]></description> <pubDate>Mon, 08 Apr 2024 06:00 GMT</pubDate> <dc:identifier>2858883</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Sirona Biochem Corp.</dc:contributor> <dc:modified>Mon, 08 Apr 2024 06:00 GMT</dc:modified> <dc:subject>Major shareholder announcements</dc:subject> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2024/04/05/2858271/0/en/Sirona-Biochem-Announces-Close-of-Private-Placement.html</guid> <link>https://www.globenewswire.com/news-release/2024/04/05/2858271/0/en/Sirona-Biochem-Announces-Close-of-Private-Placement.html</link> <category domain="https://www.globenewswire.com/rss/stock">TSX-V:SBM</category> <category domain="https://www.globenewswire.com/rss/stock">Other OTC:SRBCF</category> <category domain="https://www.globenewswire.com/rss/stock">Frankfurt:ZSB</category> <category domain="https://www.globenewswire.com/rss/stock">XETRA:ZSB</category> <category domain="https://www.globenewswire.com/rss/ISIN">CA82967M1005</category> <title>Sirona Biochem Announces Close of Private Placement</title> <description><![CDATA[<p align="justify">VANCOUVER, British Columbia, April 04, 2024 (GLOBE NEWSWIRE) -- <strong>Vancouver, British Columbia</strong> – April 4, 2024 – <a href="https://www.globenewswire.com/Tracker?data=_jHkOQAXOZ2ksPgBIxCFaP-HDPZ9BhrNy2Wved1JgfuxGmvZ2sm_AeEnS13ybkfgd3rz8inzFzk1ok1P_93Ra8hzEN-yio0lKdeoJu62W4U=" rel="nofollow" target="_blank" title="Sirona Biochem Corp">Sirona Biochem Corp</a>. (TSX-V: SBM) (Frankfurt: ZSB) (“<strong>Sirona</strong>”) has closed its private placement (Private Placement”) for gross proceeds of $132,500 CAD. The Private Placement consists of 1,325,000 units, (the “Units”) at a price of $0.10 per Unit. Each Unit consists of one common share and one transferable share purchase warrant, each whole warrant exercisable into one additional common share of the Company for a period of 2 years from the date of issue at a price of $0.15 per Share in year one and $0.25 per Share in year two. All securities issued under the Private Placement are subject to statutory hold periods expiring on August 4, 2024.<br></p>]]></description> <pubDate>Fri, 05 Apr 2024 01:24 GMT</pubDate> <dc:identifier>2858271</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Sirona Biochem Corp.</dc:contributor> <dc:modified>Fri, 05 Apr 2024 01:24 GMT</dc:modified> <dc:subject>Financing Agreements</dc:subject> <dc:subject>Changes in company's own shares</dc:subject> <dc:subject>Warrants and Certificates</dc:subject> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2024/03/28/2854520/0/en/Sirona-Biochem-Announces-2023-Annual-Meeting-Results.html</guid> <link>https://www.globenewswire.com/news-release/2024/03/28/2854520/0/en/Sirona-Biochem-Announces-2023-Annual-Meeting-Results.html</link> <category domain="https://www.globenewswire.com/rss/stock">TSX-V:SBM</category> <category domain="https://www.globenewswire.com/rss/stock">Other OTC:SRBCF</category> <category domain="https://www.globenewswire.com/rss/stock">Frankfurt:ZSB</category> <category domain="https://www.globenewswire.com/rss/stock">XETRA:ZSB</category> <category domain="https://www.globenewswire.com/rss/ISIN">CA82967M1005</category> <title>Sirona Biochem Announces 2023 Annual Meeting Results</title> <description><![CDATA[<p align="justify">VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=agFvFDRwQL2d2JSuZFN07PYaZShOmV-joXsMmsEYfLqfAPP1D61MAfgPwH9lLkzTLmYxrb1Ww2WjfcSCN-SY9mxidIRJNljwYDT03rKwHN4=" rel="nofollow" target="_blank" title="Sirona Biochem Corp.">Sirona Biochem Corp.</a> (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“<strong>Sirona</strong>”) announces the voting results from its Annual General Meeting of Shareholders (the "Meeting"), held in Vancouver, British Columbia on March 28, 2024. The total number of shares represented by shareholders present in person and by proxy at the Meeting was 26,722,196, representing 10.52% of Sirona's issued and outstanding Common Shares.<br></p>]]></description> <pubDate>Thu, 28 Mar 2024 21:00 GMT</pubDate> <dc:identifier>2854520</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Sirona Biochem Corp.</dc:contributor> <dc:modified>Thu, 28 Mar 2024 21:00 GMT</dc:modified> <dc:subject>Annual Meetings & Shareholder Rights</dc:subject> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2024/03/13/2845482/0/en/Sirona-Biochem-Receives-Commercial-Grade-GlycoProteMim-Based-Anti-Aging-Serum-Formulations.html</guid> <link>https://www.globenewswire.com/news-release/2024/03/13/2845482/0/en/Sirona-Biochem-Receives-Commercial-Grade-GlycoProteMim-Based-Anti-Aging-Serum-Formulations.html</link> <category domain="https://www.globenewswire.com/rss/stock">TSX-V:SBM</category> <category domain="https://www.globenewswire.com/rss/stock">Other OTC:SRBCF</category> <category domain="https://www.globenewswire.com/rss/stock">Frankfurt:ZSB</category> <category domain="https://www.globenewswire.com/rss/stock">XETRA:ZSB</category> <category domain="https://www.globenewswire.com/rss/ISIN">CA82967M1005</category> <title>Sirona Biochem Receives Commercial-Grade GlycoProteMim Based Anti-Aging Serum Formulations</title> <description><![CDATA[<p align="justify">VANCOUVER, British Columbia, March 13, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=pg8Vn2TItFdi0oHiGqFjLdQ91vHlMZmKBwiYYx_o6c1YSdyMzv70JSkcEphbuKugCFnigDqbnMziRQOZqBFtmskLLd512XpgzNedMbxdOfI=" rel="nofollow" target="_blank" title="Sirona Biochem Corp">Sirona Biochem Corp</a>. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“<strong>Sirona</strong>” or the “<strong>Company</strong>”) announces a significant achievement in its quest to transform the skincare industry. Its subsidiary, TFChem, has successfully received formulations for its eagerly awaited GlycoProteMim™ based anti-aging serum from its formulation partner, Global Beauty Consulting (GBC). This marks a crucial step in Sirona Biochem's plan to offer innovative skincare solutions.<br></p>]]></description> <pubDate>Wed, 13 Mar 2024 13:00 GMT</pubDate> <dc:identifier>2845482</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Sirona Biochem Corp.</dc:contributor> <dc:modified>Wed, 13 Mar 2024 13:01 GMT</dc:modified> <dc:subject>Product / Services Announcement</dc:subject> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2024/02/21/2832793/0/en/Sirona-Biochem-Announces-Plans-for-Commercial-Launch-of-GlycoProteMim-in-Early-2025.html</guid> <link>https://www.globenewswire.com/news-release/2024/02/21/2832793/0/en/Sirona-Biochem-Announces-Plans-for-Commercial-Launch-of-GlycoProteMim-in-Early-2025.html</link> <category domain="https://www.globenewswire.com/rss/stock">TSX-V:SBM</category> <category domain="https://www.globenewswire.com/rss/stock">Other OTC:SRBCF</category> <category domain="https://www.globenewswire.com/rss/stock">Frankfurt:ZSB</category> <category domain="https://www.globenewswire.com/rss/stock">XETRA:ZSB</category> <category domain="https://www.globenewswire.com/rss/ISIN">CA82967M1005</category> <title>Sirona Biochem Announces Plans for Commercial Launch of GlycoProteMim™ in Early 2025</title> <description><![CDATA[<p align="justify">VANCOUVER, British Columbia, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF), also known as Sirona, is excited to share a new milestone in its journey. A recent exclusive video interview featuring Dr. Geraldine Deliencourt-Godefroy, Sirona's Chief Scientific Officer, has been released by the Investing News Network. In this interview, Dr. Deliencourt-Godefroy unveils Sirona's ambitious plans to introduce its innovative anti-aging product, GlycoProteMimTM, to the markets of North America and Europe in early 2025.</p>]]></description> <pubDate>Wed, 21 Feb 2024 14:00 GMT</pubDate> <dc:identifier>2832793</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Sirona Biochem Corp.</dc:contributor> <dc:modified>Wed, 21 Feb 2024 14:00 GMT</dc:modified> <dc:subject>Product / Services Announcement</dc:subject> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2024/02/15/2830458/0/en/Sirona-Biochem-Provides-Update-on-Loan.html</guid> <link>https://www.globenewswire.com/news-release/2024/02/15/2830458/0/en/Sirona-Biochem-Provides-Update-on-Loan.html</link> <category domain="https://www.globenewswire.com/rss/stock">TSX-V:SBM</category> <category domain="https://www.globenewswire.com/rss/stock">Other OTC:SRBCF</category> <category domain="https://www.globenewswire.com/rss/stock">Frankfurt:ZSB</category> <category domain="https://www.globenewswire.com/rss/stock">XETRA:ZSB</category> <category domain="https://www.globenewswire.com/rss/ISIN">CA82967M1005</category> <title>Sirona Biochem Provides Update on Loan</title> <description><![CDATA[<p align="justify">VANCOUVER, British Columbia, Feb. 15, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=TjOAjKxi1wqqO_TwBur11DRedCS0Fk-6SffJBiroS4Ja_QcOzhGjOsIGaErD2-FWpW-kV7T8a6_rHlvQPrUNXRMGKawtxhZ5Zrv4S5Xt4PE=" rel="nofollow" target="_blank" title="Sirona Biochem Corp">Sirona Biochem Corp</a>. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“<strong>Sirona</strong>” or the “<strong>Company</strong>”) announce that, further to its news release on January 29, 2024, it has entered into an amendment to the demand grid promissory note dated September 22, 2023 (the “<strong>Amended Note</strong>”) with 0906462 B.C. Ltd. (the “<strong>Lender</strong>”). The Amended Note evidences a loan in the aggregate principal amount of up to $1,000,000 (the “<strong>Loan</strong>”). Pursuant to the terms and conditions of the Amended Note:<br></p>]]></description> <pubDate>Thu, 15 Feb 2024 22:50 GMT</pubDate> <dc:identifier>2830458</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Sirona Biochem Corp.</dc:contributor> <dc:modified>Thu, 15 Feb 2024 22:51 GMT</dc:modified> <dc:subject>Financing Agreements</dc:subject> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2024/02/15/2830013/0/en/Sirona-Biochem-Engages-Global-Beauty-Consulting.html</guid> <link>https://www.globenewswire.com/news-release/2024/02/15/2830013/0/en/Sirona-Biochem-Engages-Global-Beauty-Consulting.html</link> <category domain="https://www.globenewswire.com/rss/stock">TSX-V:SBM</category> <category domain="https://www.globenewswire.com/rss/stock">Other OTC:SRBCF</category> <category domain="https://www.globenewswire.com/rss/stock">Frankfurt:ZSB</category> <category domain="https://www.globenewswire.com/rss/stock">XETRA:ZSB</category> <category domain="https://www.globenewswire.com/rss/ISIN">CA82967M1005</category> <title>Sirona Biochem Engages Global Beauty Consulting</title> <description><![CDATA[<p align="justify">VANCOUVER, British Columbia, Feb. 15, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=GlTNzIEPo1_xKS4p4TVo61gmnjDNhTzdofgirt0j-mC8fzcb1_bki1LcHLLBTtwdu40_aQeJi3CdQ2J7lQKFYkHrXdcCDOO99fsPdYw7KMY=" rel="nofollow" target="_blank" title="Sirona Biochem Corp.">Sirona Biochem Corp.</a> (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“<strong>Sirona</strong>” or the “<strong>Company</strong>”) has announced its partnership with Global Beauty Consulting – Cosmetics Laboratory (GBC), under the leadership of CEO Gaël Boutry, a distinguished French formulator. GBC is currently developing an exclusive premium formulation for GlycoProteMim<sup>TM</sup> in anticipation of its launch in the first quarter of 2025.<br></p>]]></description> <pubDate>Thu, 15 Feb 2024 14:00 GMT</pubDate> <dc:identifier>2830013</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Sirona Biochem Corp.</dc:contributor> <dc:modified>Thu, 15 Feb 2024 14:01 GMT</dc:modified> <dc:subject>Business Contracts</dc:subject> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2024/01/29/2818908/0/en/Sirona-Biochem-Announces-Loan.html</guid> <link>https://www.globenewswire.com/news-release/2024/01/29/2818908/0/en/Sirona-Biochem-Announces-Loan.html</link> <category domain="https://www.globenewswire.com/rss/stock">TSX-V:SBM</category> <category domain="https://www.globenewswire.com/rss/stock">Other OTC:SRBCF</category> <category domain="https://www.globenewswire.com/rss/stock">Frankfurt:ZSB</category> <category domain="https://www.globenewswire.com/rss/stock">XETRA:ZSB</category> <category domain="https://www.globenewswire.com/rss/ISIN">CA82967M1005</category> <title>Sirona Biochem Announces Loan</title> <description><![CDATA[<p align="justify">VANCOUVER, British Columbia, Jan. 29, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=IlX342yN6PUxbu8O-_gOYYGFwT2R3tHugF_COdjZFtigBzmBWVcqmFXSuMlXwApL9irKBbhGtNhQAMcXMfw4J0UVQ4ughZjO3oeJO7ARVN4=" rel="nofollow" target="_blank" title="Sirona Biochem Corp">Sirona Biochem Corp</a>. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“<strong>Sirona</strong>” or the “<strong>Company</strong>”) announced that it has entered into a demand grid promissory note (the “<strong>Note</strong>”) with 0906462 B.C. Ltd. (the “<strong>Lender</strong>”) for a loan in the aggregate principal amount of up to $1,000,000 (the “<strong>Loan</strong>”). Pursuant to the terms and conditions of the Note:<br></p>]]></description> <pubDate>Mon, 29 Jan 2024 13:30 GMT</pubDate> <dc:identifier>2818908</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Sirona Biochem Corp.</dc:contributor> <dc:modified>Mon, 29 Jan 2024 13:30 GMT</dc:modified> <dc:subject>Financing Agreements</dc:subject> <dc:subject>Corporate Action</dc:subject> <dc:subject>Changes in company's own shares</dc:subject> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2024/01/26/2818319/0/en/Sirona-Biochem-Initiates-Private-Placement.html</guid> <link>https://www.globenewswire.com/news-release/2024/01/26/2818319/0/en/Sirona-Biochem-Initiates-Private-Placement.html</link> <category domain="https://www.globenewswire.com/rss/stock">TSX-V:SBM</category> <category domain="https://www.globenewswire.com/rss/stock">Other OTC:SRBCF</category> <category domain="https://www.globenewswire.com/rss/stock">Frankfurt:ZSB</category> <category domain="https://www.globenewswire.com/rss/stock">XETRA:ZSB</category> <category domain="https://www.globenewswire.com/rss/ISIN">CA82967M1005</category> <title>Sirona Biochem Initiates Private Placement</title> <description><![CDATA[<p align="left">VANCOUVER, British Columbia, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V:SBM) (FSE: ZSB) (OTC: SRBCF) (the "Company") is pleased to announce a non-brokered private placement of up to 10,000,000 units of the Company at a price of $0.10 CAD per Unit (a "Unit") for gross proceeds of up to CAD$1,000,000 (the "Private Placement"). Each Unit consists of one common share and one transferable share purchase warrant, each whole warrant exercisable into one additional common share of the Company for a period of 2 years from the date of issue at a price of $0.15 per Share in year one and $0.25 per Share in year two.</p>]]></description> <pubDate>Fri, 26 Jan 2024 23:07 GMT</pubDate> <dc:identifier>2818319</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Sirona Biochem Corp.</dc:contributor> <dc:modified>Fri, 26 Jan 2024 23:08 GMT</dc:modified> <dc:subject>Changes in company's own shares</dc:subject> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2024/01/24/2815680/0/en/CORRECTION-Sirona-Biochem-Corporate-Update-January-2024.html</guid> <link>https://www.globenewswire.com/news-release/2024/01/24/2815680/0/en/CORRECTION-Sirona-Biochem-Corporate-Update-January-2024.html</link> <category domain="https://www.globenewswire.com/rss/stock">TSX-V:SBM</category> <category domain="https://www.globenewswire.com/rss/stock">Other OTC:SRBCF</category> <category domain="https://www.globenewswire.com/rss/stock">Frankfurt:ZSB</category> <category domain="https://www.globenewswire.com/rss/stock">XETRA:ZSB</category> <category domain="https://www.globenewswire.com/rss/ISIN">CA82967M1005</category> <title>CORRECTION -- Sirona Biochem Corporate Update January 2024</title> <description><![CDATA[<p>VANCOUVER, British Columbia, Jan. 24, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF), please note that in the 8th paragraph of the letter, the company plans to launch its first product early in the 1<sup>st</sup> quarter of 2025, not the 1<sup>st</sup> quarter of 2024 as previously stated. The corrected release follows:</p>]]></description> <pubDate>Wed, 24 Jan 2024 16:14 GMT</pubDate> <dc:identifier>2815680</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Sirona Biochem Corp.</dc:contributor> <dc:modified>Wed, 24 Jan 2024 16:14 GMT</dc:modified> <dc:subject>Product / Services Announcement</dc:subject> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2024/01/24/2814750/0/en/Sirona-Biochem-Corporate-Update-January-2024.html</guid> <link>https://www.globenewswire.com/news-release/2024/01/24/2814750/0/en/Sirona-Biochem-Corporate-Update-January-2024.html</link> <category domain="https://www.globenewswire.com/rss/stock">TSX-V:SBM</category> <category domain="https://www.globenewswire.com/rss/stock">Other OTC:SRBCF</category> <category domain="https://www.globenewswire.com/rss/stock">Frankfurt:ZSB</category> <category domain="https://www.globenewswire.com/rss/stock">XETRA:ZSB</category> <category domain="https://www.globenewswire.com/rss/ISIN">CA82967M1005</category> <title>Sirona Biochem Corporate Update January 2024</title> <description><![CDATA[<p>VANCOUVER, British Columbia, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) provides the following update:<br></p>]]></description> <pubDate>Wed, 24 Jan 2024 06:30 GMT</pubDate> <dc:identifier>2814750</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Sirona Biochem Corp.</dc:contributor> <dc:modified>Wed, 24 Jan 2024 06:30 GMT</dc:modified> <dc:subject>Product / Services Announcement</dc:subject> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2024/01/15/2808928/0/en/Sirona-Biochem-Launches-Cosmetics-Subsidiary-Sirona-Laboratories.html</guid> <link>https://www.globenewswire.com/news-release/2024/01/15/2808928/0/en/Sirona-Biochem-Launches-Cosmetics-Subsidiary-Sirona-Laboratories.html</link> <category domain="https://www.globenewswire.com/rss/stock">TSX-V:SBM</category> <category domain="https://www.globenewswire.com/rss/stock">Other OTC:SRBCF</category> <category domain="https://www.globenewswire.com/rss/stock">Frankfurt:ZSB</category> <category domain="https://www.globenewswire.com/rss/stock">XETRA:ZSB</category> <category domain="https://www.globenewswire.com/rss/ISIN">CA82967M1005</category> <title>Sirona Biochem Launches Cosmetics Subsidiary- Sirona Laboratories™</title> <description><![CDATA[<p>VANCOUVER, Canada, Jan. 15, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) is proud to introduce Sirona Laboratories<sup>TM</sup> - a wholly-owned subsidiary dedicated to maximizing the commercial potential of its breakthrough anti-aging skincare ingredient, GlycoProteMim<sup>TM</sup>.<br></p>]]></description> <pubDate>Mon, 15 Jan 2024 06:00 GMT</pubDate> <dc:identifier>2808928</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Sirona Biochem Corp.</dc:contributor> <dc:modified>Mon, 15 Jan 2024 06:00 GMT</dc:modified> <dc:subject>Management statements</dc:subject> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2023/12/11/2793989/0/en/Sirona-Biochem-Initiates-GlycoProteMim-Trademark-for-Anti-Aging-Molecule-TFC-1326.html</guid> <link>https://www.globenewswire.com/news-release/2023/12/11/2793989/0/en/Sirona-Biochem-Initiates-GlycoProteMim-Trademark-for-Anti-Aging-Molecule-TFC-1326.html</link> <category domain="https://www.globenewswire.com/rss/stock">TSX-V:SBM</category> <category domain="https://www.globenewswire.com/rss/stock">Other OTC:SRBCF</category> <category domain="https://www.globenewswire.com/rss/stock">Frankfurt:ZSB</category> <category domain="https://www.globenewswire.com/rss/stock">XETRA:ZSB</category> <category domain="https://www.globenewswire.com/rss/ISIN">CA82967M1005</category> <title>Sirona Biochem Initiates GlycoProteMim™ Trademark for Anti-Aging Molecule TFC-1326</title> <description><![CDATA[<p>VANCOUVER, British Columbia, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF), is making a strategic move in the world of advanced skincare solutions. Today, the company announces the trademarking of its groundbreaking anti-aging and anti-wrinkle molecule, TFC-1326, as GlycoProteMim™.<br></p>]]></description> <pubDate>Mon, 11 Dec 2023 14:50 GMT</pubDate> <dc:identifier>2793989</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Sirona Biochem Corp.</dc:contributor> <dc:modified>Mon, 11 Dec 2023 14:51 GMT</dc:modified> <dc:subject>Patents</dc:subject> <dc:keyword>anti-aging</dc:keyword> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2023/10/25/2767035/0/en/Sirona-Biochem-Announces-Change-of-Auditor.html</guid> <link>https://www.globenewswire.com/news-release/2023/10/25/2767035/0/en/Sirona-Biochem-Announces-Change-of-Auditor.html</link> <category domain="https://www.globenewswire.com/rss/stock">TSX-V:SBM</category> <category domain="https://www.globenewswire.com/rss/stock">Other OTC:SRBCF</category> <category domain="https://www.globenewswire.com/rss/stock">Frankfurt:ZSB</category> <category domain="https://www.globenewswire.com/rss/stock">XETRA:ZSB</category> <category domain="https://www.globenewswire.com/rss/ISIN">CA82967M1005</category> <title>Sirona Biochem Announces Change of Auditor</title> <description><![CDATA[<p align="justify">VANCOUVER, British Columbia, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC:SRBCF) (the “Company") announces that it has changed its auditors from DeVisser Gray LLP (the “Former Auditor”) Davidson and Company (the “Successor Auditor”) effective October 25, 2023 and the board of directors of the Company appointed the Successor Auditor as the Company’s auditor effective October 25, 2023 until the next Annual General Meeting of the Company. There were no reservations in the Former Auditor’s audit reports for the relevant period, being the financial years ended October 31, 2021 and October 31, 2022 and any period subsequent to the most recently completed financial year for which an audit report was issued and preceding the resignation of the Former Auditor. In accordance with National Instrument 51-102 – Continuous Disclosure Obligations (“NI 51-102”), the Company has filed a Change of Auditor Notice (the “Notice”) on SEDAR together with letters from both the Former Auditor and Successor Auditor, with each lettering confirming agreement with the statements contained in the Notice, as applicable. There were no reportable events as defined in NI 51-102 between the Former Auditor and the Company.<br></p>]]></description> <pubDate>Wed, 25 Oct 2023 22:28 GMT</pubDate> <dc:identifier>2767035</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Sirona Biochem Corp.</dc:contributor> <dc:modified>Wed, 25 Oct 2023 22:29 GMT</dc:modified> <dc:subject>Management Changes</dc:subject> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2023/10/20/2764250/0/en/Sirona-Biochem-Announces-Payment-of-Convertible-Debenture-Interests-in-Shares.html</guid> <link>https://www.globenewswire.com/news-release/2023/10/20/2764250/0/en/Sirona-Biochem-Announces-Payment-of-Convertible-Debenture-Interests-in-Shares.html</link> <category domain="https://www.globenewswire.com/rss/stock">TSX-V:SBM</category> <category domain="https://www.globenewswire.com/rss/stock">Other OTC:SRBCF</category> <category domain="https://www.globenewswire.com/rss/stock">Frankfurt:ZSB</category> <category domain="https://www.globenewswire.com/rss/stock">XETRA:ZSB</category> <category domain="https://www.globenewswire.com/rss/ISIN">CA82967M1005</category> <title>Sirona Biochem Announces Payment of Convertible Debenture Interests in Shares</title> <description><![CDATA[<p align="center"><strong><em>N</em></strong><strong><em>O</em></strong><strong><em>T</em></strong> <strong><em>F</em></strong><strong><em>O</em></strong><strong><em>R</em></strong> <strong><em>D</em></strong><strong><em>I</em></strong><strong><em>SSE</em></strong><strong><em>M</em></strong><strong><em>I</em></strong><strong><em>N</em></strong><strong><em>A</em></strong><strong><em>T</em></strong><strong><em>I</em></strong><strong><em>O</em></strong><strong><em>N</em></strong> <strong><em>I</em></strong><strong><em>N </em></strong><strong><em>T</em></strong><strong><em>H</em></strong><strong><em>E</em></strong> <strong><em>U</em></strong><strong><em>S</em></strong> <strong><em>O</em></strong><strong><em>R</em></strong> <strong><em>T</em></strong><strong><em>H</em></strong><strong><em>R</em></strong><strong><em>O</em></strong><strong><em>U</em></strong><strong><em>G</em></strong><strong><em>H </em></strong><strong><em>U</em></strong><strong><em>S</em></strong> <strong><em>N</em></strong><strong><em>E</em></strong><strong><em>W</em></strong><strong><em>SW</em></strong><strong><em>I</em></strong><strong><em>RE</em></strong> <strong><em>SER</em></strong><strong><em>V</em></strong><strong><em>IC</em></strong><strong><em>E</em></strong><strong><em>S</em></strong><br></p>]]></description> <pubDate>Fri, 20 Oct 2023 20:50 GMT</pubDate> <dc:identifier>2764250</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Sirona Biochem Corp.</dc:contributor> <dc:modified>Fri, 20 Oct 2023 20:50 GMT</dc:modified> <dc:subject>Changes in company's own shares</dc:subject> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2023/07/13/2704404/0/en/Sirona-Biochem-Corporate-Update.html</guid> <link>https://www.globenewswire.com/news-release/2023/07/13/2704404/0/en/Sirona-Biochem-Corporate-Update.html</link> <category domain="https://www.globenewswire.com/rss/stock">TSX-V:SBM</category> <category domain="https://www.globenewswire.com/rss/stock">Other OTC:SRBCF</category> <category domain="https://www.globenewswire.com/rss/stock">Frankfurt:ZSB</category> <category domain="https://www.globenewswire.com/rss/stock">XETRA:ZSB</category> <category domain="https://www.globenewswire.com/rss/ISIN">CA82967M1005</category> <title>Sirona Biochem Corporate Update</title> <description><![CDATA[<p align="left">VANCOUVER, British Columbia, July 13, 2023 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=veZ5dvZiNoINjJnoReIc2wTfxVULlNItxz9483G6MeTvhpYPZ1TM16XgITf2sirCFC0P9iXRln5sfXzcyDxnVCfi5kwCJ5XRI36pMiPIpc0=" rel="nofollow" target="_blank" title="Sirona Biochem Corp">Sirona Biochem Corp</a>. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“<strong>Sirona</strong>”) provides the following update:<br></p>]]></description> <pubDate>Thu, 13 Jul 2023 13:00 GMT</pubDate> <dc:identifier>2704404</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Sirona Biochem Corp.</dc:contributor> <dc:modified>Thu, 13 Jul 2023 13:02 GMT</dc:modified> <dc:subject>Product / Services Announcement</dc:subject> <dc:subject>Stock Market News</dc:subject> <dc:keyword>biotech</dc:keyword> <dc:keyword>vancouver biotech</dc:keyword> <dc:keyword>anti-aging</dc:keyword> <dc:keyword>dermatology</dc:keyword> <dc:keyword>antiviral</dc:keyword> <dc:keyword>pharmaceutical</dc:keyword> <dc:keyword>skincare</dc:keyword> </item> </channel> </rss>